Bob Zhang, Author at NFCR - Page 4 of 10

Bob Zhang

2012 Prize Co-Recipient: Zhu Chen, M.D., Ph.D.

View the 2012 Press Release

View Photos from the 2012 Ceremony

Keynote Speaker: Wei Wu He, Ph.D., CEO and Chairman of OriGene Technologies, Inc.

Chairperson, Chinese Medical Association, Vice-Chairman, 12th Standing Committee of the National People’s Congress, Chairman, 15th Chinese Peasants and Workers Democratic Party, Central Committee, Former Minister of Health of the People’s Republic of China, Professor at the School of Medicine of Shanghai Jiao Tong University, Member of the Chinese Academy of Sciences, the United States National Academy of Sciences, the United States Institute of Medicine, the French Academy of Sciences, the Third World Academy of Sciences, and the European Academy of Arts, Sciences and Humanities

The Szent-Györgyi Prize Selection Committee recognizes Chen Zhu, Ph.D., for his innovative research, in collaboration with Zhen-Yi Wang, Ph.D., that led to the successful development of a new therapeutic approach to acute promyelocytic leukemia (APL).

Prof. Zhu Chen, born in Shanghai on August 17, 1953, got his master ‘s degree at Shanghai Second Medical University (present Shanghai Jiao Tong University School of Medicine) in 1981 and doctor’s degree at University Paris VII in 1989, and presently is member of the Chinese Academy of Sciences, Foreign Associate of the National Academy of Sciences and the Institute of Medicine of US, Foreign Associate of French Academy of Sciences, Honorary Fellow of the UK Academy of Medical Science, Member the Academy of Sciences for the Developing World (TWAS), Titular Member of European Academy of Arts, Sciences and Humanities, Foreign Member of Academia Europaea, External Scientific Member of the Max Planck Institute of Molecular Genetics, Director of Chinese Human Genome Center at Shanghai (CHGC), Honorary Director of Shanghai Institute of Hematology and Director of Shanghai Center for Systems Biology at Shanghai Jiao Tong University.

Prof. Zhu Chen is devoted to translational research on leukemia. He pioneered the concept of synergistic cancer targeting therapy and provided the first successful model in the treatment of acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3), which has turned this most fatal hematological malignancy to a curable disease, benefiting dozens of thousands of APL patients worldwide. The concept of synergistic targeting cancer therapy based on his translational research shed new lights on the treatment of human malignancies.

In addition to his achievements in leukemia research, Prof. Chen has been playing a major role in genomic research in China. The Chinese National Human Genome Center at Shanghai (CHGC) under his direct leadership has contributed to human genome sequencing and SNP HaploMap projects, gene discovery, and identification of the gene responsible for several human diseases. Recently, led by Prof. Chen, CHGC has accomplished Schistosoma japonicum genome sequencing and revealed features of host-parasite interplay, which may pave the way for a better control and prevention of this stubborn tropical disease.

Prof. Chen has published more than 300 papers on high-level internationally peer-reviewed journals, such as NATURE, NATURE GENETICS, SCIENCE, PNAS and BLOOD, with over 15,000 citations. He has achieved many important national and international awards and honors, including Cheung Kong Scholars Achievement Award from the National Ministry of Education, Second Degree Prize of National Natural Science Award from State Council in China, “Prix de l’Qise” by “La Ligue Nationale contre le Cancer” of France, Prix Etranger de l’INSERM of France, and “Officier de l’Ordre National de la Légion d’Honneur” by French government. Most recently, the American Society of Hematology (ASH) honored Dr. Chen with the 2016 Ernest Beutler Lecture and Prize for his significant research advances in the area of APL.

Read more

2011 Prize: Beatrice Mintz, Ph.D.

View the 2011 Press Release

View Photos from the 2011 Ceremony

Keynote Speaker: Lewis Cantley, Ph.D., Director, Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College

Professor and Jack Schultz Chair in Basic Science at Fox Chase Cancer Center, Member of the United States National Academy of Sciences, the Pontifical Academy of Sciences

The Szent-Györgyi Prize Selection Committee recognizes Beatrice Mintz, Ph.D., for her discoveries regarding the relationship between development and cancer, based on construction and analysis of chimeric and transgenic mouse models. Her work has enabled the study of cancer and other genetic diseases to be carried out within the framework of the whole organism.

Dr. Mintz first analyzed development by producing chimeric individuals in which genetically different cells coexisted throughout life. She found that normal development is based on an expanding clonal organization in which a succession of small numbers of stem cells are competent to divide or to differentiate further. In cancer, the differentiation option is diminished, while the capacity to divide increases. Thus, cancer may be regarded as an aberration of development.

Dr. Mintz was also the first to discover the importance of the microenvironment in the behavior of stem cells in the organism. Her experiments showed that when stem cells from a teratocarcinoma, a type of tumor derived from a “multipotent” stem cell, were transferred into a normal early embryo, those cells contributed, along with host cells, to development of the wide range of normally functioning tissues. This “normalization” of the tumor stem cells is attributable to the normal microenvironment in which they were placed, and this understanding has influenced many fields of biology.

The first transgenic model of malignant melanoma was produced in Dr. Mintz’s lab. This genetically engineered model is currently the only one that encompasses different subtypes of primary skin melanomas, which undergo widespread metastasis, thereby mirroring the disease in people.

Dr. Mintz is a Professor and the Jack Schultz Chair in Basic Science at the Fox Chase Cancer Center in Philadelphia, PA. She received her Ph.D. from the University of Iowa and taught at the University of Chicago before joining Fox Chase.

Read more

2010 Prize: Peter K. Vogt, Ph.D.

View the 2010 Press Release

View Photos from the 2010 Ceremony

Keynote Speaker: John Lechleiter, Ph.D., Chairman, President, and Chief Executive Officer, Eli Lilly and Company

Professor, Department of Molecular and Experimental Medicine at The Scripps Research Institute, Member of the American Academy of Arts and Sciences, the National Academy of Sciences, the Institute of Medicine of the National Academies, and the American Academy of Microbiology

The Szent-Györgyi Prize Selection Committee recognizes Peter K. Vogt, Ph.D., for his groundbreaking discovery of cancer-causing genes, which launched a new era for cancer research.

Dr. Vogt’s research, which began on a humble chicken virus in the early 1960s, has profoundly changed biology and medicine. His discovery of src, the first cancer-causing gene, or oncogene, made seminal contributions to our present understanding of the role of oncogenes, proto-oncogenes and many other critical molecular mechanisms of cancer. Today, Dr. Vogt continues to be a leader in multiple aspects of cancer research, including initiatives that use some of the most important oncogenes as therapeutic targets-initiatives that are bringing renewed hope to cancer patients.

Dr. Peter Vogt’s revolutionary research on src has led to the discovery of additional oncogenes, including myc, jun, and PI 3-kinase, that play a key role in human cancer and have become household names in the world of cellular signaling research. His current work on cancer-specific mutations in p110, the catalytic subunit of PI 3-kinase, has demonstrated that these mutations confer oncogenic activity on the protein, making them highly specific cancer targets.

Pursuing these targets, Dr. Vogt is now generating small molecule inhibitors that can interfere with their role in cancer causation. Dr. Vogt’s iconic career may have begun with oncogene discovery but it has expanded in scope and now includes translational studies aimed at developing novel therapeutic approaches for cancer patients.

Currently, Dr. Vogt is a Professor in the Department of Molecular and Experimental Medicine at The Scripps Research Institute in La Jolla, California.

He received his Ph.D. from the University of Tübingen, Germany, and trained as a virologist at the Max Planck Institute of Virology in Germany and at the University of California in Berkeley. “Dr. Vogt’s discovery of src, the first cancer causing gene, or oncogene, made seminal contributions to our present understanding of the role of oncogenes, proto-oncogenes and many other critical molecular mechanisms of cancer.”

Read more

2009 Prize: Ronald A. DePinho, M.D.

View the 2009 Press Release

View Photos from the 2009 Ceremony

Keynote Speaker: Honorable Billy Tauzin, former  president of PhARMA 

President of The University of Texas MD Anderson Cancer Center, Member of the National Academy of Sciences, Institute of Medicine of the National Academies

The Szent-Györgyi Prize Selection Committee recognizes Ronald A. DePinho, M.D., for his groundbreaking discoveries in cancer biology and for his association of aging with genetic disorders.

Dr. DePinho’s research on the life history of cancer cells includes the recognition of the mechanism of tumor suppression by the p53 gene through apoptosis activation in abnormal cell cycling. He has also shown that that INK4a/ARF is a true tumor suppressor and the genetic and biochemical linkage of ARF to the p53 pathway.

His use of inducible cancer models was notably demonstrated in Dr. DePinho’s studies of host-tumor interactions where he established the concept of “tumor maintenance” – which laid the foundation for use of the inducible model in the field and by industry for preclinical drug development. His extensive series of experiments on telomere biology reveals how telomere dysfunction may drive or suppress cancer’s development depending on the life cycle status of the tumor suppressor gene p53.

In addition to these advancements, Dr. DePinho continues to illuminate many life scientists on the link between aging and cancer – a lasting mystery for the cancer field. He has convincingly established that telomere dysfunction, combined with an impaired DNA damage response, and the removal of epithelium by aging or disease processes, converge to form the common carcinomas. Several of these discoveries have paved the way for the development of agents and therapeutics in clinical trials – including an anti-cancer telomerase inhibitor.

Dr. DePinho received his M.D. with distinction from Albert Einstein College of Medicine in the Bronx, New York.

Read more

2008 Prize: Carlo M. Croce, M.D.

View the 2008 press release

View Photos from the 2008 Ceremony

Keynote Speaker: Martin Birkhofer, M.D., Vice President, Oncology Global Medical Affairs, Bristol-Myers Squibb Research and Development

Director of the Human Cancer Genetics Program, Director of the Institute of Genetics at The Ohio State University, Member of the National Academy of Sciences and the Institute of Medicine of the National Academies

The recipient of the 2008 Albert Szent-Györgyi Prize for Progress in Cancer Research is Carlo M. Croce, M.D. The National Foundation for Cancer Research recognizes his groundbreaking discoveries that have revolutionized the field of cancer genetics and oncology over the past thirty years.

Dr. Croce’s research established the direct and causative association of chromosomal translocations with the molecular mechanisms of oncogene activation. He was the first to use specific chromosomal translocations as genetic hallmarks to identify and isolate important oncogenes and tumor suppressor genes such as BCL2, ALL1, and LZTS1, each of which revealed novel and critical signaling pathways for cancer initiation and progression. His research paved the way for entirely new avenues in the development of a variety of therapies to target cancer.

Most recently, Dr. Croce made a breakthrough discovery through his microRNA research. He provided the first evidence that these small, non-protein-coding RNAs do play a role in human cancer. Moreover, he developed a gene chip that enables the assessment of the genome-wide expression of microRNAs in normal cells and tumor tissue, and identified microRNA signatures that correlate with diagnosis and prognosis of leukemia, lung cancer, and many other types of tumors.

The most exciting aspect of his revolutionary research on microRNAs is that it reveals the tremendous potential for developing microRNA-based therapies. His discoveries mark one of the cornerstones in the field of human genetics, and will have a profound impact on furthering the development of molecular medicines for cancer patients.

Today, Dr. Croce is the Director of the Human Cancer Genetics Program and Director of the Institute of Genetics at The Ohio State University. He is also a Professor of Molecular Virology, Immunology and Medical Genetics at OSU. Dr. Croce has received numerous awards including the General Motors Cancer Research Foundation Charles S. Mott Prize, the Italian Gold Medal for Public Health presented by President Ciampi, and the G.H.A. Clowes Memorial Award of the American Association for Cancer Research. He is a member of the National Academy of Sciences, USA. He was Editor-in-Chief of Cancer Research and continues to be the Subject Editor for the British Journal of Cancer. Dr. Croce received his M.D. from the University of Rome in Rome, Italy.

Read more

2007 Prize: Webster K. Cavenee, Ph.D.

View the 2007 Press Release

View Photos from the 2007 Ceremony

Keynote Speaker: David Allan, President and Chief Executive Officer, YM Biosciences

Director, Ludwig Institute for Cancer Research, Distinguished Professor, University of California, San Diego, Member of the National Academy of Sciences and the Institute of Medicine of the National Academies

The Albert Szent-Györgyi Prize Committee selected Dr. Cavenee for his seminal discoveries in the genetic mechanisms of human cancer. Specifically, his research provided the first evidence for the existence of tumor suppressor genes, one of the most influential breakthroughs in cancer research.

Dr. Cavenee’s original research began in on defining the genetic lesions in retinoblastoma. As a result, his efforts led to the first hard experimental evidence for the existence of tumor suppressor genes. His revolutionary research on tumor suppressor genes also confirmed the “two-hit hypothesis,” fundamentally changing the conceptual framework on cancer initiation and progression. Today, mutations of tumor suppressor genes have been identified in more than half of all tumors, including those of muscle, melanocytes, kidney, prostate, and breast. Novel gene therapies to reverse gene mutations or their effects in cancer cells hold promise as cancer treatment strategies which could be beneficial to cancer patients.

Today, Dr. Cavenee, is the Director of the Ludwig Institute for Cancer Research based at the University of California, San Diego and a Professor of Medicine in the cancer biology program at UCSD. He is a Fellow of the National Foundation for Cancer Research and has won many awards, including the Charles S. Mott Prize of the General Motors Cancer Research Foundation. He is a member of the National Academy of Sciences, Past-President of the American Association for Cancer Research, a Fellow of the American Academy of Microbiology, and serves on the editorial boards of several leading scientific journals. He has also served on the Board of Scientific Counselors of the National Cancer Institute and the National Institute of Environmental Health Sciences. Cavenee received his Ph.D. from the University of Kansas Medical School.

Read more

2006 Prize: Harold F. Dvorak, M.D.

View the 2006 Press Release

View Photos from the 2006 Ceremony

Keynote Speaker: Daniel Von Hoff, M.D., FACS., TGen, Director, Professor of Medicine

Mallinckrodt Professor Emeritus of Pathology at Harvard Medical School, Chief of the Department of Pathology at Beth Israel Deaconess Medical Center

The Albert Szent-Györgyi Prize Committee selected Dr. Dvorak for his breakthrough discovery of the vascular permeability factor/vascular endothelial cell growth factor (VPF/VEGF). His contribution has led to a series of discoveries which both elucidated the mechanisms of angiogenesis as well as the development of antibodies and small molecule therapeutics to inhibit VEGF.

Today, anti-angiogenesis drugs have received FDA approval in the U.S. and 27 other countries for cancer treatments and other diseases. Largely because of Dr. Dvorak’s research, the possibility of anti-angiogenic therapy is now on a firm scientific foundation, not only in the treatment of cancer, but of many non-neoplastic diseases as well.

Dr. Dvorak is the author of over 200 original peer-reviewed papers. In addition to his distinguished accomplishments in research, Dr. Dvorak is an NFCR Fellow and past President of the American Society for Investigative Pathology. Educated at Princeton and Harvard Medical School, Dr. Dvorak finished his residency in pathology at Massachusetts General Hospital and performed his postdoctoral research at the National Institutes of Health. He has served on the Harvard Medical School faculty since 1967 and for 16 years, chaired the Department of Pathology at Beth Israel Deaconess Medical Center.

Harold F. Dvorak, M.D.
Read more

Youth Ambassador Program

The NFCR Youth Ambassador program is an opportunity for top high school students to serve as leaders in raising awareness and support for cutting-edge cancer research. Ambassadors can combine their passion for sports, science, and/or the arts with community service to bring new energy to cancer research fundraising.

NFCR Youth Ambassadors learn critical leadership skills, such as how to recruit, raise awareness, and fundraise. Plus, they learn how a national nonprofit organization functions.

With increased competition in the college application process, NFCR offers ambitious and good-natured students the chance to boost their application efforts. NFCR provides a letter of recommendation to the colleges of choice for our Ambassadors. So far, our Youth Ambassadors have applied to Brown University, the University of Cal-Berkeley, Cornell University, Emory University, the University of Maryland, the University of Michigan, Northwestern University, the University of Notre Dame and the University of Virginia.

How do You Get Started?

Call us at (301) 654-1250 or email info@nfcr.org to let us know you’re interested in becoming a Youth Ambassador. A member of the NFCR team will help get you started and brainstorm creative fundraising and recruitment ideas!

Benefits for Youth Ambassadors

  • Learn to be a community service leader
  • Strengthen critical thinking, leadership, persuasion and problem-solving skills
  • Professional, real-world work relationships
  • Receive a letter of recommendation from NFCR for resumes and college applications
  • Celebrate your successes at a year-end event hosted by NFCR. Join NFCR’s esteemed annual event – the Albert Szent-Györgyi Prize for Progress in Cancer Research reception and dinner- with members of your family

Youth Ambassador Expectations

  • Create a personal fundraising project and set a financial goal of $5,000 or more to support cancer research
  • Develop a report highlighting accomplishments and lessons learned at the end of the project
  • For projects that extend beyond one year, Ambassadors should develop a brief progress report at the end of each year
  • Bring a positive, professional attitude and commitment to amplifying the mission of NFCR
Read more

Shopping

We have partnered up with some great companies offering you ways of getting your shopping done and supporting cancer research at the same time.

Amazon Smile

Shop on Amazon and support cancer research.

GoodDeedSeats

$5 from the profits of every order to the National Foundation for Cancer Research when using code DONATECANCER at checkout.

Teleflora

Order flowers for any occasion and a portion of the proceeds will go to helping NFCR scientists in the lab.

Network for Good

Give through a leading online donation platform.

Good Cause Greetings

Shop for greeting cards for any occasion while supporting NFCR scientists.

Artline Greetings

Shop for holiday greeting cards while supporting the work of NFCR

Upside

Get huge savings on gas – up to 25¢/gal – at all the big stations in DC, MD, and VA

Just Give

The destination for online charitable giving

IGive

You Shop. NFCR Gets Money. For Free.

Goodshop

Enjoy the best shopping deals on the internet with a donation made to NFCR from every purchase you make. When you shop at Goodshop, you don’t just save, you also give, at no extra cost.

Charity Choice

Donate, honor, purchase or send a gift card that allows the beneficiary to support NFCR.

Fan Signer

Enjoy personalized sports memorabilia from your favorite athletes while helping support NFCR.

SPAGnVOLA

NFCR is partnering with one of the top 10 chocolates shops in the world! Please contact Nancy at Nancy.Stempel@spagnvola.com or 301-788-3571 to place your order today and tell her you want to support NFCR or use code NFCR18 when purchasing online.

Read more

Honor & Memorial Gifts

Donate in Honor or Memory


A gift made to the National Foundation of Cancer Research is a wonderful way to honor and remember loved ones and special events.

  • EASY
    It’s a simple, one-step way to say “I’m thinking about you” and “I want to make a difference in the lives of others.”
  • FLEXIBLE
    You have the choice to make a one time or recurring gift.
  • PERSONAL
    For all gifts over $10, a beautiful, personalized card can be sent to the person of your choice to let them know a donation has been made.
  • TAX DEDUCTIBLE
    All donations are tax-deductible, in full accordance with federal laws.

Donate to the Rose Fund


Creating or donating to the Rose Fund is a quick and simple way to create a memorial fund or lasting tribute in honor of someone you love.  

  • MEANINGFUL
    A Rose Fund will bear the name of the loved one you select.
  • PERMANENT
    The Fund lasts indefinitely– contributions can be made at any time, over many years.
  • STRAIGHTFORWARD
    There are no set up fees, no minimums and no recurring monthly donation requirements.
  • TAX DEDUCTIBLE
    All donations are tax-deductible, in full accordance with federal laws.

Your gift today will help us fund groundbreaking cancer research. If you would like to browse and donate to an existing Rose Fund, please click here.

Read more